FDA Requires GLP-1 Drugs to Add Vision-Loss Warning to Labels
The agency cited a rare optic nerve condition called NAION after reviewing 126 clinical trials and observational data linking the blockbuster drug class to sudden, potentially permanent sight loss.
The Food and Drug Administration told makers of GLP-1 drugs on Nov. 9 that they must add a warning to their labels about a rare but serious eye condition that can cause sudden, permanent vision loss. The mandate covers the entire class, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound.
The condition at issue is non-arteritic anterior ischemic optic neuropathy, or NAION. Clinicians sometimes call it an "eye stroke" because it's driven by reduced blood flow to the optic nerve. According to CBS News, it can cause blurred vision, blind spots, and distorted color perception, and the vision loss it produces tends to be irreversible even after a patient stops the medication.
The FDA's move wasn't a snap judgment. According to a physician analysis published in The Conversation, the agency compiled data from 126 randomized, controlled clinical trials before concluding the signal was strong enough to act on. Those trials enrolled more than 134,000 patients, roughly 78,000 on a GLP-1 drug and 56,000 on placebo or a comparator. The agency also reviewed observational studies and a 2024 research article that first flagged a possible link, as reported by The National News.
The FDA said cases of NAION have been reported with every GLP-1 drug currently on the market, according to NBC News. Patients with a prior history of NAION are at higher risk.
What the warning does not do is quantify how often the problem occurs. The FDA described the risk as rare, and several ophthalmologists quoted across outlets were careful to put that in clinical context. Manjot Gill, an ophthalmologist at Northwestern Medicine, told NBC News that the warning label mandate was appropriate, but added that patients already on these medications for a diabetes or obesity indication shouldn't simply stop. The Conversation's physician contributor put it plainly: the data shows a real but low risk, and for most patients taking the drug on medical advice, it shouldn't be the deciding factor.
That framing matters. Right now, roughly 15 million people in the United States take a GLP-1 drug, according to a review published in PubMed-indexed literature. With numbers that large, even a low-frequency adverse event shows up in pharmacovigilance data, and the FDA's job at that point is to put the information in front of prescribers and patients, not to make the clinical call for them.
What clinicians will need to do now is screen patients for NAION risk factors before starting the drugs, and have a clear conversation about visual symptoms to watch for. The FDA's listed warning signs include blurred vision, sudden loss of vision in one eye, and color disturbances. Patients who notice those symptoms while on a GLP-1 should contact an eye doctor promptly, the agency said.
For patients who've been on Ozempic or Wegovy for years without trouble, the practical upshot is straightforward: know the symptoms, tell your doctor if something changes in your vision, and don't discontinue without talking to whoever manages your diabetes or weight-related care first. The risk is rare. The vision loss, if it happens, is not.
Sources cited:
- CBS News (https://www.cbsnews.com/news/glp-1-vision-loss-side-effect-warning-fda/)
- The Conversation (https://theconversation.com/glp-1-drugs-carry-risk-of-rare-but-serious-eye-condition-a-physician-studying-these-medicines-explains-the-potential-side-effect-296237)
- The National News (https://www.thenationalnews.com/future/science/2026/11/10/do-glps1s-cause-blindness/)
- NBC News (https://www.nbcnews.com/health/health-care/fda-orders-new-warning-glp-1s-rare-eye-condition-linked-sudden-blindne-rcna608309)
This release was originally distributed via ETL Newswire. Visit CBS News for the full story, related releases, and contact information.
Visit CBS News →